All In Biotech

Investigational drug · Phase 2

AMT-253

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Melanoma, Advanced Solid Tumors.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "AMT-253"

First trial start

2024

Jan 31, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AMT-253", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Malignant Melanoma
  • Advanced Solid Tumors

Approved drugs for the same conditions: Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "AMT-253" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Malignant Melanoma

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • DNA VaccinePhase 22 trials

    NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)

  • RAPA-201 Rapamycin Resistant T CellsRAPA-201 cellsPhase 22 trials

    Rapa Therapeutics LLC · Malignant Melanoma, Malignant Melanoma With Metastasis, Malignant Melanoma Stage IIIc

  • TCC1727Phase 22 trials

    Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)

  • GM103Phase 21 trial

    GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.